CAS: 1233322-09-2

BI-69A11 is a dual AKT/NFkB inhibitor, increasing colon cancer cell sensitivity to mda-7/IL-24.

(E)-3-(1H-Benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one is a novel anticancer drug that is currently undergoing clinical trials. It has been shown to induce autophagy and apoptosis in cancer cells and may be a potential treatment for various types of cancer. The mechanism by which (E)-3-(1H-Benzo[d]imidazol-2-yl)-1-(6,6'-dichloro)-2,4'-biphenylquinoline induces autophagy is not fully understood but may involve the following: (i) activation of AMP kinase via the mTOR pathway; (ii) induction of PGC1α expression; and (iii) inhibition of AKT phosphorylation. Mesenchymal

BI-69A11